CTRI/2018/12/016771尚未招募未知
A randomized controlled trial comparing safety and efficacy of intravenous iron sucrose and ferric carboxymaltose in moderate iron deficiency anemia in pregnant women.
Department of OBGY0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Pregnant woman with confirmed moderate iron deficiency anemia (7to 10 gm/dl)
- •Singleton pregnancy
- •Gestational age between 28 to 34 week
排除标准
- •Pregnant woman with anemia other than iron deficiency
- •Known case of allergy to iron injection
- •Multiple pregnancy
- •Hypertension
- •Diabetes mellitus
- •Chronic liver disease
- •Renal disorder
- •Cardiovascular disease
- •Thyroid disorder
- •Intestinal resection,bypass
- •Hemosiderosis
- •Hemochromatosis
研究者
相似试验
招募中
不适用
A study to check if C-Reactive Protein is needed before stopping antibiotics in newborn babies suspected to have bacterial infection whose blood cultures are negativeCTRI/2020/05/025440CMC hospital Vellore
尚未招募
4 期
Comparison of inhalational new drug vilanterol fluticasone furoate combination with salmeterol fluticasone furoate combination for reversible respiratory obstructive disease.CTRI/2024/04/066334Central Research And Publication Unit
进行中（未招募）
不适用
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB (with effusion) - IV Non-Small Cell Lung Cancer (NSCLC) - ESCAPEEUCTR2005-005245-19-DEBayer Pharmaceuticals Corporation900
进行中（未招募）
不适用
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)on Small Cell Lung CancerMedDRA version: 8.1Level: PTClassification code 10061873EUCTR2005-005245-19-HUBayer Pharmaceuticals Corporation900
进行中（未招募）
1 期
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)EUCTR2005-005245-19-ESBayer Pharmaceuticals Corporation